ID Biomedical announced that Dr. Scott Halperin of the Clinical Trials Research Center at IWK Health Centre and Dalhousie University in Halifax, Nova Scotia, presented Phase I Clinical Trial results for the FluINsure(TM) flu vaccine at the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Diego, CA. The FluINsure flu vaccine is the Company's intranasally administered, non-living vaccine for the prevention of influenza.

The clinical trial demonstrated that FluINsure(TM), which is a trivalent product, was strongly immunogenic. Statistically-significant increases in both serum hemagglutination inhibiting (HAI) antibody and in virus-specific secretory IgA antibodies in the nose were shown for all three types of influenza viruses (A/H1N1, A/H3N2, and B) represented in the vaccine. Serum HAI antibody is an accepted correlate of immunity to influenza, and nasal secretory IgA antibody responses have received attention as an additional marker of disease resistance induced by live, attenuated nasal influenza vaccines. In addition, FluINsure was well-tolerated by healthy adults in this randomized, double-blinded, and placebo-controlled trial. Only mild and short-lived runny nose was associated with the active vaccine when compared to placebo. 'Based on the results of this trial, the FluINsure flu vaccine appears to be quite competitive, in terms of both safety and immunogenicity, with other nasal flu vaccines,'said Dr. Halperin.

'These are very encouraging results,'said Dr. Louis Fries, Vice President for Clinical and Regulatory Affairs. 'Across all subjects who got active vaccine, the average increase in serum HAI antibody levels to all three viruses was 3.2-fold. However, if you consider those subjects who entered the study with levels of serum HAI antibody below the presumed protective level - those who needed protection - the average increase was 5.3-fold. Virus-specific nasal IgA responses, which are technically harder to measure, were also strong in both all subjects and in subjects without clear pre-existing immunity, averaging 2.3 to 2.6-fold. While the two-dose group did have larger antibody rises, we were pleased to see significant immune responses in every treatment group. Overall, we saw significant, potentially protective, serum and/or nasal antibody responses in 71, 87, and 90% of subjects who entered the study without evidence of existing immunity to the A/H1N1, A/H3N2, or B viruses, respectively.'

The FluINsure flu vaccine is currently undergoing Phase II testing to further define an optimal dosing regimen. Results from the Phase II study are expected in Q4 2002. Subsequently, the Company plans to evaluate the vaccine in one or more challenge trials.

FluINsure is based on the Company's proprietary Proteosome(TM) vaccine delivery/adjuvant technology. The flu vaccine is created by combining Proteosome proteins with a purified preparation of influenza proteins that includes the hemagglutinin protein. Importantly, unlike some other nasal influenza vaccines in development, FluINsure contains no live viruses. Intranasal vaccines based on the Proteosome delivery system, and incorporating a variety of different antigens, have now been tested in over 360 people and have had a very encouraging safety profile.

About ID Biomedical

ID Biomedical is a North American based biotechnology company focused on the development of proprietary subunit vaccine products, including those based on its Proteosome(TM) platform intranasal adjuvant/delivery technology. ID Biomedical has also developed a proprietary genomics analysis system, Cycling Probe(TM) Technology.

ID Biomedical is developing subunit vaccines for the prevention of a number of different diseases. The Company's lead products in clinical development are the FluINsure(TM) intranasal influenza (flu) vaccine and the StreptAvax(TM) group A streptococcal vaccine. Additionally, the Company has a number of vaccines in preclinical development.

ID Biomedical is licensing Cycling Probe Technology as well as its broad patents in signal amplification to the genomics and diagnostic industry for further products and technology development. Several companies have obtained rights to ID Biomedical's patent portfolio.

The foregoing information contains so-called forward-looking statements. These include statements about ID Biomedical's expectations, beliefs, intentions or strategies for the future, which it indicates by words or phrases such as 'anticipate', 'expect', 'intend', 'plan', 'will', 'we believe', 'ID Biomedical believes', 'management believes'and similar language. All forward-looking statements are based on ID Biomedical's current expectations and are subject to risks uncertainties and to assumptions made. Important factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include: (i) the ability to successfully complete preclinical and clinical development of its products; ii) the ability to obtain and enforce timely patent and intellectual property protection for its technology and products; iii) the ability to avoid, either by product design, licensing arrangement or otherwise, infringement of third parties'intellectual property; iv) decisions, and the timing of decisions, made by

the health regulatory agencies regarding approval of its products for human testing; v) the ability to complete and maintain corporate alliances relating to the development and commercialization of its technology and products; vi) market acceptance of its technology and product; and (vii) the competitive environment and impact of technological change. ID Biomedical bases its forward-looking statements on information currently available to it, and assumes no obligation to update them.

CONTACT: TEL: (604) 431-9314 ID Biomedical Corporation

Dean Linden, Manager, Corporate Communications

INET : www.idbiomedical.com